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ABSTRACT  
Objective: To develop a new, simple and sensitive visible spectrophotometric method for the estimation of Cilnidipine [CIL] in bulk and tablet 
dosage forms.  
Methods: The visible spectrophotometric method was based on the color reaction of CIL with N-(1-Naphthyl) ethylene diamine dihydrochloride 
reagent [it is stable for 20 min] to form a purple coloured chromophore that has an absorption maxima at 554 nm. The method was validated as per 
ICH guidelines.  
Results: Beer’s law was obeyed over the concentration range of 16-24 μg/mL for Cilnidipine. Limit of detection [LOD] and limit of quantification 
[LOQ] are 0.4365 and 1.3228 respectively. The average recovery was found to be 100.43% w/w. 
Conclusion: The method developed is precise, linear and accurate. Satisfactory results were obtained from validation of the method. Hence the 
proposed method is suitable in quality control of estimation Cilnidipine bulk and pharmaceutical dosage forms.  
Keywords: Cilnidipine, Visible spectrophotometry, N-(1-Naphthyl) ethylene diamine dihydrochloride, Validation, ICH guidelines.  
 
INTRODUCTION 
Cilnidipine [CIL] is chemically, 1,4- Dihydro- 2,6- dimethyl- 4-(3-
nitrophenyl)-3,5-pyridinecarboxylic acid 2-methoxyethyl(2E)-3-
phenyl-propenyl ester. It is a dual blocker of L-type voltage-gated 
calcium channels in vascular smooth muscle and N-type calcium 
channels in sympathetic nerve terminals that supply blood 
vessels[1,2].  
The literature survey revealed the lack of a visible 
spectrophotometric method for the estimation of CIL. However 
estimation of the drug as a single molecule and in combination with 
other drugs by UV spectrophotometric, HPLC and HPTLC was 
available[3-17].  
The aim of present work was to develop an improved 
spectrophotometric method with greater precision and accuracy. 
The proposed method is mainly based on the reaction of Cilnidipine 
with N-(1-Naphthyl) ethylene diamine dihydrochloride (NED) 
reagent which gives purple color chromophore that has an 
absorption maximum at 554 nm. The structural formula for CIL is 
shown in Fig 1. 
 
Fig. 1: Structure of Cilnidipine (C27H28N2O7
 
) 
MATERIALS AND METHODS 
Instrumentation  
A Shimadzu UV/visible double beam spectrophotometer (model 
Lambda 25) with 1 cm matched quartz cells were used for all the 
spectral measurements. 
Chemicals and Reagents 
Pharmaceutical grade Cilnidipine was obtained as gift samples from 
Ideal Analytical and Research Institute, India. The pharmaceutical 
dosage form used in this study was Cilacar tablets (J. B. Chemical and 
Pharmaceuticals Ltd., Mumbai, India) labeled to contain 20 mg of 
Cilnidipine was procured from the market. Double distilled 
methanol was used. All other chemicals used were of Analar grade. 
All the aqueous solutions were prepared in double distilled water. 2 
M hydrochloric acid, Sodium nitrite (0.1%w/v), Ammonium 
sulphamate (0.5%w/v), NED reagent (0.1%w/v) solutions were 
prepared in double distilled water. 
Preparation of stock solution 
The stock solution was prepared by dissolving 100 mg pure 
Cilnidipine in 25 mL of methanol in to 100 mL volumetric flasks and 
sonicated for 15 min. Then volume was made up to 100 mL with 
distilled water to give a concentration of 1 mg/mL. 
Recommended procedure and calibration graph 
Transfer increasing volumes of the filtrate, covering the range 16 – 
24 mg/mL into a series of 50 mL volumetric flasks. Add 5 mL of 2M 
HCl and the mixtures are shaken. Then 5 mL of 0.1 %w/v sodium 
nitrite solution is added and the mixtures are allowed to stand for 2 
minutes. Then 5 mL of 0.5 %w/v ammonium sulphamate solution is 
added and is allowed to stand for 2 minutes. After that 5 mL of 0.1 
%w/v NED was added and the volumes are made up to the mark 
with methanol. After 10 minutes, the absorbance of the Purple 
chromogen was measured against a reagent blank, prepared in the 
same manner but without CIL at 554 nm.  
Procedure for the tablet dosage form 
Ten tablets (20 mg / tablet) were weighed and finely powdered. A 
portion of the powder equivalent to 100 mg of the drug was weighed 
in to a 100 mL volumetric flask and dissolved in 25 mL of methanol 
and was sonicated for 15 minutes. Then the volume was madwe 
upto the mark with distilled water. The solution was shaken well, 
filtered and an aliquot of the filtered drug solution was the treated 
as done in the recommended procedure. 
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The developed method was validated as per the International 
Conference on Harmonization (ICH) [18-19] guidelines with respect 
to linearity and range, precision, accuracy, limit of detection (LOD) 
and limit of quantization (LOQ). The values were analyzed by 
statistical methods.  
Linearity 
The linearity of measurement was evaluated by analyzing different 
concentrations of the standard solution of CIL. Beer-Lambert’s 
concentration range was found to be 16-24 μg/mL. The overlay 
spectra and calibration graph are shown in Figure 2 and 3 
respectively. The optical parameters are given in Table 1. 
 
 
Fig. 2: Overlay spectrum of cilnidipine showing linearity 
 
 
Fig. 3: Calibration curve of cilnidipine 
 
Limit of detection (LOD) and limit of quantitation (LOQ) 
The LOD and LOQ of CIL were determined by using standard 
deviation of the response and slope approach as defined in the 
International Conference on Harmonization (ICH) guidelines. The 
LOD and LOQ data presented in Table 1. 
Accuracy 
To ascertain the accuracy of proposed method, recovery studies 
were carried out by standard addition method at three different 
levels (80%, 100% and 120%). Percent recovery of CIL was found in 
the range of 98.3 – 102 %w/w (Table 2). 
 
Table 1: Optical Characteristics and Other Parameters 
Parameter Results 
Regression equation  y = 0.0208X + 0.0084 
λmax 554  (nm) 
Beer’s law limits (μg/mL) 16-24 
Slope 0.02 
Intercept 0.008 
Correlation Coefficient 0.999 
LOD (μg/mL) 0.4365 
LOQ(μg/mL) 1.3228 
Table 2: Recovery Study Data. 
Preanalysed 
Quantity 







6 10 16.15 101.00 
10 10 20.22 102.00 
14 10 23.83 98.30 
 
Precision 
Precision is determined by using the same method used to assay the 
sample and repeated for a sufficient number of times to obtain 
statistically valid result. The experimental values were determined 
by Intra and interday. The values are validated by statistical 
analysis. The precision is then expressed as the relative standard 
deviation. % RSD was found to be 1.08665 and 0.89205 for intraday 
and Interday respectively. 
RESULTS AND DISCUSSION 
CIL is a new calcium channel antagonist used as antihypertensive 
agent. It showed maximum absorbance at 240 nm. Linearity was 
obeyed in concentration range of 3-18 μg/ml. As the values of % RSD 
of all precision study were within the acceptable limits (less than 2 
%), the method provides good precision and reproducibility. The % 
RSD less than 2 indicated that the method was accurate. Results of 
the recovery study were found to be within the acceptance criteria 
linear, accurate, precise and reproducible. 
CONCLUSION 
A visible Spectrophotometric method has been developed for the 
determination of CIL in bulk and tablet formulation. The method was 
validated based on ICH analytical method validation guidelines. The 
method was found to be accurate, linear, precise and reproducible. 
Hence the method can be used for routine analysis of CIL in bulk and 
tablet formulation. 
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